Sorrento Therapeutics Inc
Change company Symbol lookup
Select an option...
SRNE Sorrento Therapeutics Inc
EOG EOG Resources Inc
CPLP Capital Product Partners LP
BVNNF Bevcanna Enterprises Inc
OCUL Ocular Therapeutix Inc
GOOG Alphabet Inc
BAC Bank of America Corp
ED Consolidated Edison Inc
FRAN Francesca's Holdings Corp
CWBHF Charlotte's Web Holdings Inc
Go

Health Care : Biotechnology | Small Cap Value
Company profile

Sorrento Therapeutics, Inc. is a clinical-stage and commercial biopharma company. The Company operates through two segments: Sorrento Therapeutics and Scilex. The Sorrento Therapeutics segment is organized around its Immune-Oncology therapeutic area, leveraging its G-MAB antibody library and targeted delivery modalities to generate the next generation of cancer therapeutics. These modalities include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy (DAR-T), antibody-drug conjugates (ADC), as well as bispecific antibody approaches. Additionally, Sorrento Therapeutics segment also includes Sofusa, a drug delivery technology that delivers biologics directly into the lymphatic system to potentially achieve improved efficacy and fewer adverse effects than standard parenteral immunotherapy. The Scilex segment is organized around its non-opioid pain management operations.

Closing Price
$9.43
Day's Change
-0.05 (-0.53%)
Bid
--
Ask
--
B/A Size
--
Day's High
9.46
Day's Low
8.64
Volume
(Average)
Volume:
35,168,066

10-day average volume:
34,365,421
35,168,066

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of SRNE, CEMI and JCOM

10:53 am ET July 27, 2020 (Accesswire) Print

NEW YORK, NY / ACCESSWIRE / July 27, 2020 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.

Sorrento Therapeutics, Inc. (NASDAQ:SRNE)Class Period: May 15, 2020 - May 22, 2020Lead Plaintiff Deadline: July 27, 2020

The complaint alleges that throughout the class period Sorrento Therapeutics, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) the Company's initial finding of "100% inhibition" in an in vitro virus infection will not necessarily translate to success or safety in vivo, or in person; (ii) the Company's finding was not a "cure" for COVID-19; and (ii) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Learn about your recoverable losses in SRNE: http://www.kleinstocklaw.com/pslra-1/sorrento-therapeutics-inc-loss-submission-form?id=8190&from=1

Chembio Diagnostics, Inc. (NASDAQ:CEMI)Class Period: March 12, 2020 - June 16, 2020Lead Plaintiff Deadline: August 17, 2020

According to the filed complaint, defendants engaged in a scheme to deceive the market and a course of conduct that artificially inflated Chembio's stock price and operated as a fraud or deceit by misrepresenting the efficacy of the Company's Dual Path Platform ("DPP") COVID-19 test. Defendants allegedly achieved this by making false statements about Chembio's DPP COVID-19 test, although they knew or at least recklessly disregarded that there were material performance concerns with the test. When defendants' prior misrepresentations were disclosed and became apparent to the market, the price of Chembio stock fell precipitously as the prior artificial inflation came out of Chembio's stock price.

Learn about your recoverable losses in CEMI: http://www.kleinstocklaw.com/pslra-1/chembio-diagnostics-inc-loss-submission-form?id=8190&from=1

J2 Global, Inc. (NASDAQ:JCOM)Class Period: October 5, 2015 - June 29, 2020Lead Plaintiff Deadline: September 8, 2020

The complaint alleges that during the class period J2 Global, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) J2 Global engaged in undisclosed related party transactions; (2) J2 Global used misleading accounting to hide requisite impairments and underperformance in acquisitions; (3) several so-called independent members of the Company' board of directors and audit committee were not disinterested; and (4) as a result, Defendants' public statements were materially false and/or misleading at all relevant times.

Learn about your recoverable losses in JCOM: http://www.kleinstocklaw.com/pslra-1/j2-global-inc-loss-submission-form?id=8190&from=1

Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.

J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

J. Klein, Esq.Empire State Building350 Fifth Avenue59th FloorNew York, NY 10118jk@kleinstocklaw.comTelephone: (212) 616-4899Fax: (347) 558-9665www.kleinstocklaw.com

SOURCE: The Klein Law Firm

View source version on accesswire.com: https://www.accesswire.com/599035/The-Klein-Law-Firm-Reminds-Investors-of-Class-Actions-on-Behalf-of-Shareholders-of-SRNE-CEMI-and-JCOM

comtex tracking

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.